Monday Jun 3
A Premature Death? KV Pharmaceutical and Makena Make an Unexpected Comeback
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today! Ever since the scandal erupted over compounding pharmacies and a national outbreak of fungal meningitis, KV Pharmaceuticals has been telling the FDA 'we told you so.' Now, the drugmaker, which landed in bankruptcy after a pricing controversy over its Makena ... (more)
KV reports $3.5 million loss for April
Bridgeton-based KV Pharmaceutical reported a net loss of $3.5 million for the month ended April 30, on revenue of $8.3 million, according to a recent filing with the U.S. Securities and Exchange Commission .